Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Gastroenterology

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.4093